Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises
source: Pediatric Emergency Care
year: 2019
authors: Hagedorn JM, Monico EC
summary/abstract:OBJECTIVES:
Sickle cell disease is the most common hemoglobin variant in the world and can present with recurrent vaso-occlusive painful crises. Pain control in these patients is often difficult and requires a multimodal approach. In patients with uncontrolled pain after traditional pain control methods, ketamine infusions have proven beneficial. Unfortunately, no source alone had described ketamine infusions for pediatric sickle cell patients. Our objective was to provide a thorough definitive reference for health care providers regarding the use of ketamine infusion for pain control in pediatric sickle cell painful crises.
METHODS:
Literature review.
RESULTS:
Low-dose ketamine infusions for pediatric patients with sickle cell disease painful crises resulted in improved pain scores and reduced opioid usage.
CONCLUSIONS:
Ketamine infusions have shown promise in assisting physicians in appropriately treating pediatric sickle cell painful crises.
DOI: 10.1097/PEC.0000000000000978
read more full text
Related Content
-
Outcomes of an Emergency Department Observation Unit–Based Pathway for the Treatment of Uncomplicated Vaso-Occlusi...Study objective: This was a prospective...
-
Angela Rivers, MD, PhDDr. Rivers is the Director at Sickle Cel...
-
Brenda Martin, CPNP-PCBrenda Martin is a pediatric nurse pract...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic PainObjective: These evidence-based guideli...
-
Grant Recipient Uses Mobile Device Observation in Sickle Cell Pain StudyTechnology takes center stage in a new...
-
BCL11A-based gene therapy for sickle cell disease passes key preclinical testA precision-engineered gene therapy viru...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.